Literature DB >> 33433723

Kratom Alkaloids, Natural and Semi-Synthetic, Show Less Physical Dependence and Ameliorate Opioid Withdrawal.

Lisa L Wilson1, Soumen Chakraborty2, Shainnel O Eans1, Thomas J Cirino1, Heather M Stacy1, Chloe A Simons1, Rajendra Uprety3, Susruta Majumdar2, Jay P McLaughlin4.   

Abstract

Chronic administration of opioids produces physical dependence and opioid-induced hyperalgesia. Users claim the Thai traditional tea "kratom" and component alkaloid mitragynine ameliorate opioid withdrawal without increased sensitivity to pain. Testing these claims, we assessed the combined kratom alkaloid extract (KAE) and two individual alkaloids, mitragynine (MG) and the analog mitragynine pseudoindoxyl (MP), evaluating their ability to produce physical dependence and induce hyperalgesia after chronic administration, and as treatments for withdrawal in morphine-dependent subjects. C57BL/6J mice (n = 10/drug) were administered repeated saline, or graded, escalating doses of morphine (intraperitoneal; i.p.), kratom alkaloid extract (orally, p.o.), mitragynine (p.o.), or MP (subcutaneously, s.c.) for 5 days. Mice treated chronically with morphine, KAE, or mitragynine demonstrated significant drug-induced hyperalgesia by day 5 in a 48 °C warm-water tail-withdrawal test. Mice were then administered naloxone (10 mg/kg, s.c.) and tested for opioid withdrawal signs. Kratom alkaloid extract and the two individual alkaloids demonstrated significantly fewer naloxone-precipitated withdrawal signs than morphine-treated mice. Additional C57BL/6J mice made physically dependent on morphine were then used to test the therapeutic potential of combined KAE, mitragynine, or MP given twice daily over the next 3 days at either a fixed dose or in graded, tapering descending doses. When administered naloxone, mice treated with KAE, mitragynine, or MP under either regimen demonstrated significantly fewer signs of precipitated withdrawal than control mice that continued to receive morphine. In conclusion, while retaining some liabilities, kratom, mitragynine, and mitragynine pseudoindoxyl produced significantly less physical dependence and ameliorated precipitated withdrawal in morphine-dependent animals, suggesting some clinical value.

Entities:  

Keywords:  Kratom; Mitragynine; Opioid; Physical dependence; Withdrawal

Mesh:

Substances:

Year:  2021        PMID: 33433723      PMCID: PMC8164968          DOI: 10.1007/s10571-020-01034-7

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   4.231


  55 in total

Review 1.  Mitragyna speciosa, a psychoactive tree from Southeast Asia with opioid activity.

Authors:  Jessica E Adkins; Edward W Boyer; Christopher R McCurdy
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

2.  Ondansetron does not prevent physical dependence in patients taking opioid medications chronically for pain control.

Authors:  Larry F Chu; Tom Rico; Erika Cornell; Hannah Obasi; Ellen M Encisco; Haley Vertelney; Jamison G Gamble; Clayton W Crawford; John Sun; Anna Clemenson; Matthew J Erlendson; Robin Okada; Ian Carroll; J David Clark
Journal:  Drug Alcohol Depend       Date:  2017-08-14       Impact factor: 4.492

3.  Rewarding or aversive effects of buprenorphine/naloxone combination (Suboxone) depend on conditioning trial duration.

Authors:  Corinne Canestrelli; Nicolas Marie; Florence Noble
Journal:  Int J Neuropsychopharmacol       Date:  2014-03-10       Impact factor: 5.176

4.  A case of uncommon withdrawal symptoms after a short period of spinal morphine administration.

Authors:  Jacques Devulder; Peter Bohyn; Frédéric Castille; Martine De Laat; Georges Rolly
Journal:  Pain       Date:  1996-03       Impact factor: 6.961

5.  Thermal sensitivity as a measure of spontaneous morphine withdrawal in mice.

Authors:  Rebecca E Balter; Linda A Dykstra
Journal:  J Pharmacol Toxicol Methods       Date:  2013-02-14       Impact factor: 1.950

6.  Acute thermal hyperalgesia elicited by low-dose morphine in normal mice is blocked by ultra-low-dose naltrexone, unmasking potent opioid analgesia.

Authors:  S M Crain; K F Shen
Journal:  Brain Res       Date:  2001-01-05       Impact factor: 3.252

7.  Long-lasting hyperalgesia induced by fentanyl in rats: preventive effect of ketamine.

Authors:  E Célèrier; C Rivat; Y Jun; J P Laulin; A Larcher; P Reynier; G Simonnet
Journal:  Anesthesiology       Date:  2000-02       Impact factor: 7.892

8.  Ondansetron Does Not Reduce Withdrawal in Patients With Physical Dependence on Chronic Opioid Therapy.

Authors:  Larry F Chu; John Sun; Anna Clemenson; Matthew J Erlendson; Tom Rico; Erika Cornell; Hannah Obasi; Zahra N Sayyid; Ellen M Encisco; Jeff Yu; Jamison G Gamble; Ian Carroll; J David Clark
Journal:  J Addict Med       Date:  2017 Sep/Oct       Impact factor: 3.702

9.  Self-treatment of opioid withdrawal using kratom (Mitragynia speciosa korth).

Authors:  Edward W Boyer; Kavita M Babu; Jessica E Adkins; Christopher R McCurdy; John H Halpern
Journal:  Addiction       Date:  2008-06       Impact factor: 6.526

10.  Predicted Mode of Binding to and Allosteric Modulation of the μ-Opioid Receptor by Kratom's Alkaloids with Reported Antinociception In Vivo.

Authors:  Yuchen Zhou; Steven Ramsey; Davide Provasi; Amal El Daibani; Kevin Appourchaux; Soumen Chakraborty; Abhijeet Kapoor; Tao Che; Susruta Majumdar; Marta Filizola
Journal:  Biochemistry       Date:  2020-12-04       Impact factor: 3.162

View more
  12 in total

1.  Oxidative Metabolism as a Modulator of Kratom's Biological Actions.

Authors:  Soumen Chakraborty; Rajendra Uprety; Samuel T Slocum; Takeshi Irie; Valerie Le Rouzic; Xiaohai Li; Lisa L Wilson; Brittany Scouller; Amy F Alder; Andrew C Kruegel; Michael Ansonoff; Andras Varadi; Shainnel O Eans; Amanda Hunkele; Abdullah Allaoa; Sanjay Kalra; Jin Xu; Ying Xian Pan; John Pintar; Bronwyn M Kivell; Gavril W Pasternak; Michael D Cameron; Jay P McLaughlin; Dalibor Sames; Susruta Majumdar
Journal:  J Med Chem       Date:  2021-11-16       Impact factor: 7.446

2.  Understanding Opioid Actions, Pain and Analgesia: A Tribute to Dr. Gavril Pasternak.

Authors:  Kelly M Standifer; Charles E Inturrisi; Kathleen M Foley; Ying-Xian Pan
Journal:  Cell Mol Neurobiol       Date:  2021-05-12       Impact factor: 5.046

3.  Physiological dependence to mitragynine indicated by a rapid cross-dependence procedure with heroin-dependent mice.

Authors:  Kai Yue; Jonathan L Katz; Xiji Shu
Journal:  Psychopharmacology (Berl)       Date:  2022-02-02       Impact factor: 4.530

4.  A Novel Mitragynine Analog with Low-Efficacy Mu Opioid Receptor Agonism Displays Antinociception with Attenuated Adverse Effects.

Authors:  Soumen Chakraborty; Jeffrey F DiBerto; Abdelfattah Faouzi; Sarah M Bernhard; Anna M Gutridge; Steven Ramsey; Yuchen Zhou; Davide Provasi; Nitin Nuthikattu; Rahul Jilakara; Melissa N F Nelson; Wesley B Asher; Shainnel O Eans; Lisa L Wilson; Satyanarayana M Chintala; Marta Filizola; Richard M van Rijn; Elyssa B Margolis; Bryan L Roth; Jay P McLaughlin; Tao Che; Dalibor Sames; Jonathan A Javitch; Susruta Majumdar
Journal:  J Med Chem       Date:  2021-09-10       Impact factor: 8.039

5.  Case Report: Treatment of Kratom Use Disorder With a Classical Tricyclic Antidepressant.

Authors:  Alessandro E Vento; Simone de Persis; Sergio De Filippis; Fabrizio Schifano; Flavia Napoletano; John M Corkery; Georgios D Kotzalidis
Journal:  Front Psychiatry       Date:  2021-03-31       Impact factor: 4.157

Review 6.  Experimental considerations for the assessment of in vivo and in vitro opioid pharmacology.

Authors:  Rob Hill; Meritxell Canals
Journal:  Pharmacol Ther       Date:  2021-07-10       Impact factor: 12.310

7.  Site selective C-H functionalization of Mitragyna alkaloids reveals a molecular switch for tuning opioid receptor signaling efficacy.

Authors:  Srijita Bhowmik; Juraj Galeta; Václav Havel; Melissa Nelson; Abdelfattah Faouzi; Benjamin Bechand; Mike Ansonoff; Tomas Fiala; Amanda Hunkele; Andrew C Kruegel; John E Pintar; Susruta Majumdar; Jonathan A Javitch; Dalibor Sames
Journal:  Nat Commun       Date:  2021-06-22       Impact factor: 14.919

8.  Therapeutic benefit with caveats?: Analyzing social media data to understand the complexities of kratom use.

Authors:  Kirsten E Smith; Jeffrey M Rogers; Destiny Schriefer; Oliver Grundmann
Journal:  Drug Alcohol Depend       Date:  2021-06-25       Impact factor: 4.852

9.  Kratom Alkaloids as Probes for Opioid Receptor Function: Pharmacological Characterization of Minor Indole and Oxindole Alkaloids from Kratom.

Authors:  Soumen Chakraborty; Rajendra Uprety; Amal E Daibani; Valerie L Rouzic; Amanda Hunkele; Kevin Appourchaux; Shainnel O Eans; Nitin Nuthikattu; Rahul Jilakara; Lisa Thammavong; Gavril W Pasternak; Ying-Xian Pan; Jay P McLaughlin; Tao Che; Susruta Majumdar
Journal:  ACS Chem Neurosci       Date:  2021-07-02       Impact factor: 5.780

Review 10.  Influence of G protein-biased agonists of μ-opioid receptor on addiction-related behaviors.

Authors:  Lucja Kudla; Ryszard Przewlocki
Journal:  Pharmacol Rep       Date:  2021-04-09       Impact factor: 3.024

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.